MarketCap
Facebook
X
Telegram
STERIS plc Revenue | STE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue STERIS plc
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.94 B | 5.46 B | 5.14 B | 4.54 B | 1.11 B | 3.11 B | 3.03 B | 2.78 B | 2.62 B | 2.61 B | 2.24 B | 1.85 B | 1.62 B | 1.5 B | 1.41 B | 1.21 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.94 B | 1.11 B | 2.89 B |
Quarterly Revenue STERIS plc
| 2027-Q1 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.49 B | 1.5 B | 1.46 B | 1.39 B | 1.5 B | 1.46 B | 1.39 B | - | 1.37 B | 1.33 B | 1.28 B | - | 1.3 B | 1.24 B | 1.18 B | - | 1.22 B | 1.2 B | 1.16 B | 1.21 B | 1.21 B | 3.37 B | 2.17 B | 968 M | 809 M | 809 M | 756 M | 669 M | 774 M | 774 M | 737 M | 697 M | 696 M | 679 M | 639 M | 716 M | 662 M | - | 608 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.37 B | 608 M | 1.15 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
32 M | $ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
10.4 B | $ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
507 M | $ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
1.33 B | $ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
86.6 M | $ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
143 M | $ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
320 M | $ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
18.8 M | $ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.72 B | $ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
77.5 M | $ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
738 M | $ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
535 M | $ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
239 M | $ 19.8 | 1.62 % | $ 981 M | USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
96.2 M | $ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
11.2 B | $ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
569 M | $ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
5.65 B | $ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
71.6 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |